November 8, 2024
On October 10, 2024, the MaRS Discovery District in Toronto was abuzz with excitement as over 200 life science industry leaders, investors, and researchers gathered for the inaugural UHNLeashed Commercialization & Partnering Showcase. Hosted by Commercialization at UHN, this event showcased cutting-edge biomedical innovations and fostered meaningful partnerships aimed at transforming game-changing research into real-world medical applications.
The showcase featured a day packed with inspiring keynote presentations, dynamic breakout sessions, and a thought-provoking panel on harnessing the power of AI and data in health care.
View event highlights here.
%20(2).png)
August 27, 2024
Accelerator Fund Announces Inaugural Recipients
We are pleased to announce Drs. Sarah Crome, Pamela Ohashi and Shin Ogawa receive a total of $750,000 in internal funding through the Innovation Accelerator stream to further advance their work towards commercialization:
Dr. Sarah Crome (TGHRI) is focused on advancing cell therapeutics to improve clinical outcomes for stem cell transplantations.
Dr. Shinichiro (Shin) Ogawa (McEwen) is developing a novel stem cell-based liver regenerative therapy for patients with liver failure.
Dr. Pamela Ohashi (PM) seeks to develop and validate a novel cell therapeutic agent to improve immunotherapy for cancer patients.
.png)
September 25, 2023
Congratulations to University Health Network incubated company Adela on its next financing round! Proceeds from this second financing will be used to advance health options for cancer patients.
July 14, 2023
Nanogenix™ aims to develop emerging photo-immune cancer treatments. The company’s core technology is based on is based on Dr. Gang Zheng’s decade of research on naturally occurring lipid-based nanoparticles.
April 24, 2023
UHN tech ensures precise delivery of radiation during treatment and is now used world-wide
%20-%20featured%20news%20card.png)
October 3, 2024
Newest study further validates sensitivity of cancer detection test being developed at Adela, whose single liquid biopsy platform can be applied across multiple cancer types
%20(2).png)
November 18, 2021
Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform. Financing led by Sino Biopharmaceutical and 3W Fu...
March 2, 2022
A cancer research discovery made at the University Health Network and The Hospital for Sick Children has spurred a major pharmaceutical industry deal between Pfizer Inc. and Trillium Therapeutics.
